Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-596
Closed -$59K 1728
2025
Q2
$59K Sell
596
-332
-36% -$31.4K ﹤0.01% 1517
2025
Q1
$86K Sell
928
-230
-20% -$21.2K ﹤0.01% 1568
2024
Q4
$105K Buy
1,158
+503
+77% +$46.2K ﹤0.01% 1518
2024
Q3
$63K Buy
+655
New +$63.9K ﹤0.01% 1591
2024
Q2
Sell
-436
Closed -$40K 1847
2024
Q1
$40K Hold
436
﹤0.01% 1662
2023
Q4
$41K Sell
436
-151
-26% -$14.1K ﹤0.01% 1656
2023
Q3
$55K Buy
+587
New +$54.2K ﹤0.01% 1366
2020
Q1
Sell
-4,742
Closed -$792K 1285
2019
Q4
$792K Sell
4,742
-4,369
-48% -$650K 0.01% 967
2019
Q3
$1.19M Sell
9,111
-4,206
-32% -$548K 0.01% 810
2019
Q2
$1.62M Sell
13,317
-983
-7% -$117K 0.01% 674
2019
Q1
$1.76M Sell
14,300
-9,723
-40% -$1.22M 0.01% 649
2018
Q4
$2.81M Sell
24,023
-23,435
-49% -$2.76M 0.03% 456
2018
Q3
$5.93M Buy
47,458
+28,861
+155% +$3.19M 0.04% 394
2018
Q2
$1.59M Sell
18,597
-24,827
-57% -$1.82M 0.01% 663
2018
Q1
$2.62M Hold
43,424
0.02% 522
2017
Q4
$2.29M Hold
43,424
0.02% 570
2017
Q3
$2.43M Hold
43,424
0.02% 563
2017
Q2
$2.73M Sell
43,424
-52,043
-55% -$3.03M 0.03% 514
2017
Q1
$4.88M Sell
95,467
-10,724
-10% -$511K 0.04% 415
2016
Q4
$4.53M Buy
106,191
+19,187
+22% +$816K 0.04% 416
2016
Q3
$4.13M Buy
87,004
+19,135
+28% +$955K 0.05% 386
2016
Q2
$3.43M Buy
67,869
+44,111
+186% +$2.23M 0.05% 403
2016
Q1
$1.15M Sell
23,758
-10,945
-32% -$422K 0.02% 615
2015
Q4
$1.36M Buy
34,703
+12,346
+55% +$494K 0.03% 549
2015
Q3
$849K Sell
22,357
-23,903
-52% -$1.01M 0.02% 634
2015
Q2
$1.84M Sell
46,260
-14,987
-24% -$467K 0.02% 583
2015
Q1
$1.64M Buy
61,247
+27,563
+82% +$778K 0.02% 602
2014
Q4
$989K Buy
+33,684
New +$832K 0.01% 752

Other funds holding AMED

KBC Group's AMED Position: Q3 2025 in Review

KBC Group sold out of Amedisys (AMED) in Q3 2025, closing a stake of 596 shares — an estimated $59K sold.

KBC Group first reported a position in AMED in Q4 2014 and held it in 28 quarters. The position peaked at $5.93M in Q3 2018. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.

  • KBC Group reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
  • KBC Group sold 596 Amedisys shares in Q3 2025, an estimated $59K.
  • KBC Group first reported a position in Amedisys in Q4 2014 and held it in 28 quarters.
  • KBC Group's Amedisys position peaked at $5.93M in Q3 2018.
  • 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.

Based on KBC Group's 13F filing for Q3 2025, filed 20 Jan 2026.